SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Swami Vivekananda Synthetic CCD — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientVivekananda
Date of birth1863-01-12
IdentifiersMRN HR-NI032-SYN-TD; SSN (made up) 000-32-9014
Document date2026-11-01
AuthorAnjali Thornbury-Mensah, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

New patient visit for thirst, frequent urination, tiredness and weight loss in a 35-year-old monk told of diabetes a year ago and never tested: examination, random glucose and urine tests, and planning of fasting tests to confirm and classify diabetes; long-standing insomnia; raised blood pressure. Concerns: He is thirsty, up at night to pass urine, tired and losing weight, and wants to know whether he truly has diabetes and what kind; He wants any treatment to fit his monastic life: his diet, his fasts and his travel; He has never been able to fall asleep easily, and broken nights now leave him exhausted. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Metformin extended-release 500 mg tablets: two tablets (1000 mg) with the evening meal, starting with one for the first week1000 mg with the evening mealOral route1898-02-16 to 1898-03-23completedS
Metformin extended-release 500 mg tablets: four tablets (1872 mg) with the evening meal; on fast days with the meal that ends the fast; hold if vomiting, diarrhea or unable to drink1872 mg with the evening mealOral route1898-03-23activeS
Losartan 25 mg oral tablet, one tablet dailyOne tablet dailyOral route1898-03-09activeS
Atorvastatin 10 mg oral tablet, one tablet dailyOne tablet dailyOral route1898-03-23activeS
Prednisone 20 mg oral tablet, two tablets (40 mg) each morning for five days40 mg each morning for five daysOral route1898-10-20 to 1898-10-24completedS
Budesonide-formoterol 160/4.5 mcg inhaler with a spacer, one inhalation as needed for wheeze or breathlessness, no more than 12 inhalations a day, until lung function testingOne inhalation as neededRespiratory tract route1898-10-20 to 1898-10-27completedS
Empagliflozin 10 mg oral tablet, one tablet each morning; skip it on any day of fasting without water, and stop it when unable to eat or drinkOne tablet dailyOral route1898-10-27activeS
Budesonide-formoterol 160/4.5 mcg inhaler with a spacer as maintenance and reliever (GINA track 1, step 3): one inhalation twice daily and one as needed, no more than 12 inhalations a dayOne inhalation twice daily plus one as neededRespiratory tract route1898-10-27activeS

Procedures

ProcedureDatesStatusEvidence
Comprehensive diabetic foot examination: skin intact; pulses present; 10-g monofilament and vibration sense normal at all sites1898-02-16 to 1898-02-16completedS
Diabetes self-management education and medical nutrition therapy referral: a dietitian visit to build a meal plan around his monastery diet and fasts1898-02-16 to 1898-02-16completedS
Advance care planning conversation, about 20 minutes, with his consent1898-03-09 to 1898-03-09completedS
Diabetic retinopathy screening with retinal photographs of both eyes: no retinopathy; no macular edema1898-03-23 to 1898-03-23completedS
Chest X-ray, posteroanterior and lateral: mild hyperinflation; heart size normal; no pulmonary edema, effusion or consolidation1898-10-20 to 1898-10-20completedS
Resting 12-lead ECG: sinus tachycardia at 106 per minute; normal axis and intervals; no ischemic change1898-10-20 to 1898-10-20completedS
Spirometry before and 15 minutes after albuterol 400 mcg, with FeNO, interpreted with GLI Global race-neutral equations: FEV1 2.95 L (77 percent predicted) rising to 3.42 L (+470 mL, +16 percent); FEV1/FVC 0.66 before and 0.75 after; FeNO 44 ppb. Reversible airflow obstruction: asthma1898-10-27 to 1898-10-27completedS
Written asthma action plan with peak flow zones (green above 470 L/min, yellow 300 to 470, red below 300, from his predicted value until a personal best is set), given and explained1898-10-27 to 1898-10-27completedS
Inhaler technique with a spacer, taught and checked by teach-back: correct1898-10-27 to 1898-10-27completedS

Immunizations

DateVaccineStatusEvidence
1898-02-16Influenza vaccine, this seasoncompletedS
1898-02-16COVID-19 mRNA vaccine, this season's formulacompletedS
1898-02-16Pneumococcal conjugate vaccine PCV20completedS
1898-03-09Tdap vaccine (no record of a tetanus vaccine in adulthood)completedS
1898-03-09Hepatitis B vaccine (HepB-CpG), dose 1 of 2completedS
1898-10-27Hepatitis B vaccine (HepB-CpG), dose 2 of 2completedS
1898-10-27Influenza vaccine, the new seasoncompletedS
1898-10-27COVID-19 mRNA vaccine, the new season's formulacompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
March 1897Diabetes, as he described it in his letters, after his return to India at about 34; physicians advised the cool air of Darjeeling and rest; he wrote that eating only meat and drinking no water seemed the only way to prolong his life; how it was diagnosed is not recordedD (CLM-0005)
May 29, 1897Lifelong difficulty falling asleep, in his own words: unable to sleep on getting into bed, tossing for at least two hoursD (CLM-0006)

Family History

RelativeConditionAge at deathEvidence
family memberDiabetes, which he called "a hereditary foe"; no relative is named and no detail is recordedD (CLM-0005)

Health Concerns

ConcernStatusEvidence
He is thirsty, up at night to pass urine, tired and losing weight, and wants to know whether he truly has diabetes and what kindactiveS
He wants any treatment to fit his monastic life: his diet, his fasts and his travelactiveS
He has never been able to fall asleep easily, and broken nights now leave him exhaustedactiveS

Assessment

Most recent measures: Glucose [Mass/volume] in Serum or Plasma 124 on 1898-10-27; Sodium [Moles/volume] in Serum or Plasma 136 on 1898-02-09; Potassium [Moles/volume] in Serum or Plasma 4.5 on 1898-10-27; Creatinine [Mass/volume] in Serum or Plasma 0.98 on 1898-10-27; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1893)/1.73 sq M 103 on 1898-10-27; Hemoglobin [Mass/volume] in Blood 14.6 on 1898-02-09; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 1898-10-27; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 1898-03-09; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 2 on 1898-03-09; Total score [AUDIT-C] 0 on 1898-03-09; Maximum expiratory gas flow Respiratory system airway by Peak flow meter 330 on 1898-10-20; Hemoglobin A1c/Hemoglobin.total in Blood 6.9 on 1898-10-27; Glutamate decarboxylase 65 Ab [Units/volume] in Serum by Immunoassay 1.2 on 1898-02-16; C peptide [Mass/volume] in Serum or Plasma 2.6 on 1898-02-16; Albumin/Creatinine [Mass Ratio] in Urine 34 on 1898-10-27; Cholesterol [Mass/volume] in Serum or Plasma 152 on 1898-10-27; Cholesterol in HDL [Mass/volume] in Serum or Plasma 39 on 1898-10-27; Triglyceride [Mass/volume] in Serum or Plasma 146 on 1898-10-27; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 84 on 1898-10-27; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 38 on 1898-02-16; Thyrotropin [Units/volume] in Serum or Plasma 1.8 on 1898-02-16; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 312 on 1898-02-16; FEV1 --pre bronchodilation 2.95 on 1898-10-27; FEV1 --post bronchodilation 3.42 on 1898-10-27; FEV1 measured/predicted 77 on 1898-10-27; FEV1/FVC 0.66 on 1898-10-27; FEV1/FVC --post bronchodilation 0.75 on 1898-10-27; Fractional concentration of exhaled nitric oxide 44 on 1898-10-27; Total score [ACT] 15 on 1898-10-27 [S]

Strengths and supports: Supports: his brother monks and disciples, who share his daily life; his faith and practice. He wants his care to fit his vows and his duties, and he alone decides it [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Thirst, frequent urination day and night, tiredness and about 4 kg weight loss over two months, with a random glucose of 246 mg/dL; told by physicians a year ago that he had diabetes, never confirmed with modern tests or treated except by diet. Diabetes to be confirmed and classified (type 2, type 1 or slowly progressive autoimmune diabetes) with A1c, fasting glucose, GAD antibodies and C-peptideresolvedconfirmed R73.9S — Synthetic presenting problem anchored to his documented diabetes of the year before. Superseded by the diagnosis at the second visit.
Type 2 diabetes: A1c 9.4 percent and fasting glucose 172 mg/dL, with symptoms; GAD65 antibodies negative and fasting C-peptide preserved (2.6 ng/mL); no ketones. BMI 24.6, in the range where ADA screens Asian Americans. Classified as type 2, not type 1 or slowly progressive autoimmune diabetesactiveconfirmed E11.65S — Synthetic modern confirmation and classification linked to his documented diabetes.
Moderately increased albuminuria on a first sample (urine albumin-to-creatinine ratio 46 mg/g), eGFR normal; to be confirmed on two of three samples over three to six monthsresolvedconfirmed R80.9S — Synthetic finding linked to his documented albuminuria; superseded when diabetic kidney disease was confirmed.
Raised blood pressure in clinic (138/86, average of two readings) without a diagnosis of hypertension; home readings to be takenresolvedconfirmed R03.0S — Synthetic finding; not a claim about his real blood pressure.
Hypertension, stage 1: clinic 138/86, 136/86 and 134/84; home average 136/86 over seven days; with moderately increased albuminuria and diabetesactiveconfirmed I10S — Synthetic finding of the modern episode; not a claim about his real blood pressure, which was never recorded.
Long-standing difficulty falling asleep: by his own account he has never been able to fall asleep on getting into bed and lies awake for two hours or more most nights; worse lately with waking to pass urine; rises before dawn for meditationactiveconfirmed G47.00S — Synthetic modern problem linked to his documented lifelong difficulty falling asleep.
Mixed hyperlipidemia: LDL cholesterol 132 mg/dL, triglycerides 228, HDL 36activeconfirmed E78.2S — Synthetic cardiovascular risk factor.
Attacks of wheeze and breathlessness for three weeks since coming down from the mountains to the damp plains, the worst last night with a sense of suffocation: peak flow 330 L/min (56 percent of predicted), oxygen saturation 94 percent, rising to 410 L/min after bronchodilator; no fever, edema or chest pain; chest X-ray and ECG without heart failure or pneumonia. Asthma to be confirmed with spirometryresolvedconfirmed R06.2S — Synthetic presenting problem anchored to his documented suffocating attacks of asthma on his return to Belur. Superseded by the diagnosis a week later.
Asthma, adult onset, confirmed: FEV1 2.95 L (77 percent predicted) rising 470 mL (16 percent) after bronchodilator, FEV1/FVC 0.66 rising to 0.75; FeNO 44 ppb; brought on by damp air and smoke; one moderate attack treated with prednisoneactiveconfirmed J45.40S — Synthetic modern confirmation linked to his documented attacks of asthma.
Diabetic kidney disease, CKD stage G1 A2: moderately increased albuminuria on three samples over eight months (46, 41 and 34 mg/g) with eGFR above 90activeconfirmed E11.21S — Synthetic modern diagnosis linked to his documented albuminuria and Bright's disease; not a claim about the cause of his real kidney disease.

Results

DateMeasureValueUnitReference rangeFlagProvenance
1898-02-09Glucose [Mass/volume] in Serum or Plasma246mg/dLRandom sample; 200 mg/dL or more with symptoms suggests diabetesHighS
1898-02-09Sodium [Moles/volume] in Serum or Plasma136mmol/L135-145 mmol/LNormalS
1898-02-09Potassium [Moles/volume] in Serum or Plasma4.3mmol/L3.5-5.1 mmol/LNormalS
1898-02-09Creatinine [Mass/volume] in Serum or Plasma0.96mg/dL0.74-1.35 mg/dLNormalS
1898-02-09Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1893)/1.73 sq M106mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1898-02-09Hemoglobin [Mass/volume] in Blood14.6g/dL13.5-17.5 g/dLNormalS
1898-02-09Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S
1898-03-09Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S
1898-03-09Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]2{score}S
1898-03-09Total score [AUDIT-C]0{score}S
1898-10-20Maximum expiratory gas flow Respiratory system airway by Peak flow meter330L/min80 percent of his predicted 590 L/minLowS
1898-02-16Hemoglobin A1c/Hemoglobin.total in Blood9.4%Below 5.7% is normal; 6.5% or more diabetes; his target below 7%HighS
1898-02-16Glucose [Mass/volume] in Serum or Plasma172mg/dLFasting; 126 mg/dL or more indicates diabetesHighS
1898-02-16Glutamate decarboxylase 65 Ab [Units/volume] in Serum by Immunoassay1.2[IU]/mLBelow 5 IU/mL negativeNormalS
1898-02-16C peptide [Mass/volume] in Serum or Plasma2.6ng/mL0.8-3.5 ng/mLNormalS
1898-02-16Albumin/Creatinine [Mass Ratio] in Urine46mg/g30 to 299 moderately increased; 300 or more severely increasedHighS
1898-02-16Cholesterol [Mass/volume] in Serum or Plasma214mg/dL<=199 mg/dLHighS
1898-02-16Cholesterol in HDL [Mass/volume] in Serum or Plasma36mg/dL40 mg/dL or more for menLowS
1898-02-16Triglyceride [Mass/volume] in Serum or Plasma228mg/dL<=149 mg/dLHighS
1898-02-16Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation132mg/dL<=99 mg/dLHighS
1898-02-16Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma38U/L7-55 U/LNormalS
1898-02-16Thyrotropin [Units/volume] in Serum or Plasma1.8m[IU]/L0.4-4 mIU/LNormalS
1898-02-16Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma312pg/mL232-1245 pg/mLNormalS
1898-03-23Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
1898-03-23Creatinine [Mass/volume] in Serum or Plasma1mg/dL0.74-1.35 mg/dLNormalS
1898-03-23Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1893)/1.73 sq M101mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1898-03-23Albumin/Creatinine [Mass Ratio] in Urine41mg/g30 to 299 moderately increased; 300 or more severely increasedHighS
1898-10-27Hemoglobin A1c/Hemoglobin.total in Blood6.9%Below 5.7% is normal; 6.5% or more diabetes; his target below 7%HighS
1898-10-27Glucose [Mass/volume] in Serum or Plasma124mg/dLFasting; 126 mg/dL or more indicates diabetesHighS
1898-10-27Albumin/Creatinine [Mass Ratio] in Urine34mg/g30 to 299 moderately increased; 300 or more severely increasedHighS
1898-10-27Potassium [Moles/volume] in Serum or Plasma4.5mmol/L3.5-5.1 mmol/LNormalS
1898-10-27Creatinine [Mass/volume] in Serum or Plasma0.98mg/dL0.74-1.35 mg/dLNormalS
1898-10-27Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1893)/1.73 sq M103mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1898-10-27Cholesterol [Mass/volume] in Serum or Plasma152mg/dL<=199 mg/dLNormalS
1898-10-27Cholesterol in HDL [Mass/volume] in Serum or Plasma39mg/dL40 mg/dL or more for menLowS
1898-10-27Triglyceride [Mass/volume] in Serum or Plasma146mg/dL<=149 mg/dLNormalS
1898-10-27Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation84mg/dL<=99 mg/dLNormalS
1898-10-27FEV1 --pre bronchodilation2.95LLower limit of normal; predicted 3.85 L; lower limit of normal 3.10 L (GLI Global race-neutral equations)LowS
1898-10-27FEV1 --post bronchodilation3.42LLower limit of normal; predicted 3.85 L; lower limit of normal 3.10 L (GLI Global race-neutral equations)NormalS
1898-10-27FEV1 measured/predicted77%GLI Global race-neutral equationsLowS
1898-10-27FEV1/FVC0.66{ratio}Lower limit of normal for his age (GLI Global)LowS
1898-10-27FEV1/FVC --post bronchodilation0.75{ratio}Lower limit of normal for his age (GLI Global)NormalS
1898-10-27Fractional concentration of exhaled nitric oxide44[ppb]Above 50 ppb high; 25 to 50 intermediate (ATS)HighS
1898-10-27Total score [ACT]15{score}S
1898-10-27Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
1898-02-09Body height172cmS
1898-02-09Body weight73kgS
1898-02-09Body mass index (BMI) [Ratio]24.7kg/m2S
1898-02-09Systolic blood pressure138mm[Hg]S
1898-02-09Diastolic blood pressure86mm[Hg]S
1898-02-09Heart rate84/minS
1898-02-09Respiratory rate16/minS
1898-02-09Body temperature36.8CelS
1898-02-09Oxygen saturation in Arterial blood by Pulse oximetry98%S
1898-02-16Body height172cmS
1898-02-16Body weight72.8kgS
1898-02-16Body mass index (BMI) [Ratio]24.6kg/m2S
1898-02-16Systolic blood pressure136mm[Hg]S
1898-02-16Diastolic blood pressure86mm[Hg]S
1898-02-16Heart rate80/minS
1898-02-16Respiratory rate16/minS
1898-02-16Body temperature36.7CelS
1898-02-16Oxygen saturation in Arterial blood by Pulse oximetry98%S
1898-03-09Body height172cmS
1898-03-09Body weight73.4kgS
1898-03-09Body mass index (BMI) [Ratio]24.8kg/m2S
1898-03-09Systolic blood pressure134mm[Hg]S
1898-03-09Diastolic blood pressure84mm[Hg]S
1898-03-09Heart rate76/minS
1898-03-09Respiratory rate14/minS
1898-03-09Body temperature36.7CelS
1898-03-09Oxygen saturation in Arterial blood by Pulse oximetry98%S
1898-03-23Body height172cmS
1898-03-23Body weight73.8kgS
1898-03-23Body mass index (BMI) [Ratio]24.9kg/m2S
1898-03-23Systolic blood pressure128mm[Hg]S
1898-03-23Diastolic blood pressure80mm[Hg]S
1898-03-23Heart rate74/minS
1898-03-23Respiratory rate14/minS
1898-03-23Body temperature36.6CelS
1898-03-23Oxygen saturation in Arterial blood by Pulse oximetry98%S
1898-10-20Body height172cmS
1898-10-20Body weight74.6kgS
1898-10-20Body mass index (BMI) [Ratio]25.2kg/m2S
1898-10-20Systolic blood pressure132mm[Hg]S
1898-10-20Diastolic blood pressure82mm[Hg]S
1898-10-20Heart rate108/minS
1898-10-20Respiratory rate24/minS
1898-10-20Body temperature36.9CelS
1898-10-20Oxygen saturation in Arterial blood by Pulse oximetry94%S
1898-10-27Body height172cmS
1898-10-27Body weight74.8kgS
1898-10-27Body mass index (BMI) [Ratio]25.3kg/m2S
1898-10-27Systolic blood pressure126mm[Hg]S
1898-10-27Diastolic blood pressure78mm[Hg]S
1898-10-27Heart rate82/minS
1898-10-27Respiratory rate16/minS
1898-10-27Body temperature36.6CelS
1898-10-27Oxygen saturation in Arterial blood by Pulse oximetry97%S

Encounters

DatePurposeStatusProvenance
1898-02-09New patient visit for thirst, frequent urination, tiredness and weight loss in a 35-year-old monk told of diabetes a year ago and never tested: examination, random glucose and urine tests, and planning of fasting tests to confirm and classify diabetes; long-standing insomnia; raised blood pressurefinishedS
1898-02-16Diagnosis visit with the endocrinology consultation: A1c, fasting glucose, GAD antibodies, C-peptide, urine albumin, lipids and B12; type 2 diabetes confirmed; metformin by shared decision; nutrition and fasting plansfinishedS
1898-03-23Five-week diabetes review before a long journey: glucose log, metformin dose, kidney function and potassium on losartan, repeat urine albumin, retinal photographs, statin, and a travel and fasting planfinishedS
1898-10-27Review after seven months away and a week after an asthma attack: A1c, kidneys, lipids, spirometry with bronchodilator response and FeNO; asthma and diabetic kidney disease confirmed; empagliflozin and maintenance-and-reliever inhaler; fasting plan for the coming festivalfinishedS
1898-03-09Periodic preventive visitfinishedS
1898-10-20Same-day sick visit for an asthma attack after returning from the mountainsfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Endocrinology consultation in one week, the same day as fasting blood tests, to confirm and classify diabetes (A1c, fasting glucose, GAD antibodies, C-peptide), and advise on treatment that fits his diet, his religious fasts and his travelcompletedGL-ADA-DX-2026, GL-ADA-PHARM-2026, GL-CMID-2026S
Diagnostic tests in one week, fasting: A1c, fasting plasma glucose, GAD65 antibodies, C-peptide, urine albumin-to-creatinine ratio, lipid panel, ALT, TSH and vitamin B12; urine ketones negative today; drink water freely while thirsty and avoid waterless fasts until the results are known; return the same day if vomiting, abdominal pain or drowsinesscompletedGL-ADA-DX-2026, GL-ADA-PHARM-2026, GL-CMID-2026, GL-ADA-COMORB-2026S
Home blood pressure readings twice daily for a week with a validated upper-arm cuff, because clinic readings are raisedcompletedGL-ADA-CVD-2026, GL-CMID-2026S
Insomnia: sleep diary for two weeks, screening for sleep apnea, and cognitive behavioral therapy for insomnia adapted to his pre-dawn meditation; no sleeping tablets, by his preference; nocturia to be reviewed once glucose is treatedcompletedGL-ACP-INS-2016, GL-AASM-INS-2021S
Metformin extended-release with the evening meal, titrated to 1872 mg, chosen by shared decision over early combination therapy or an injected GLP-1 receptor agonist; home glucose meter; diabetes education and medical nutrition therapy for a mostly vegetarian plan built on his monastery meals, his choices and his fasts; sulfonylureas avoided because of fastingcompletedGL-ADA-PHARM-2026, GL-ADA-BEH-2026, GL-SA-PLANT-2022, GL-CMID-2026S
Religious fasting plan adapted from IDF-DAR risk stratification: fasts with fruit, milk and water allowed; waterless fasts only once glucose is steady, with hydration; metformin with the meal that ends the fast; glucose checks at midday and before breaking the fast; break the fast below 70 or above 300 mg/dL or when unwellcompletedGL-IDF-DAR-2021, GL-ADA-BEH-2026S
Vaccines for an adult with diabetes: influenza and COVID-19 each season, PCV20 once, hepatitis B (two doses) and TdapcompletedGL-CDC-IMZ-MC-2026, GL-CDC-IMZ-2026S
Hypertension with albuminuria: losartan 25 mg daily (an ARB rather than an ACE inhibitor, to avoid cough), less salt, home readings, potassium and creatinine two weeks after startingcompletedGL-ADA-CVD-2026, GL-ADA-CKD-2026, GL-CMID-2026S
Cardiovascular prevention: atorvastatin 10 mg daily at 35 with diabetes, South Asian ancestry, albuminuria and hypertension, by his choice; lipid panel six to twelve weeks after startingcompletedGL-ADA-CVD-2026, GL-SOUTHASIAN-2013, GL-CMID-2026S
Travel plan for months away: medicine and test-strip supply, sick-day rules (hold metformin and losartan when vomiting, with diarrhea or unable to drink), monthly messages with readings, and A1c, urine albumin and lipids at three months wherever he iscompletedGL-ADA-PHARM-2026, GL-CMID-2026S
Asthma attack in a man with diabetes: prednisone 40 mg for five days with glucose checks before breakfast and the evening meal and a call for readings above 300 mg/dL; as-needed budesonide-formoterol until spirometry; review within a weekcompletedGL-GINA-2025, GL-ADA-GLY-2026S
Diabetic kidney disease G1 A2: empagliflozin 10 mg each morning, skipped on waterless fast days and stopped with metformin when unable to eat or drink; losartan continued; potassium, creatinine and urine albumin in three months, then every six monthscompletedGL-ADA-CKD-2026, GL-KDIGO-CKD-2024, GL-IDF-DAR-2021S
Asthma on GINA track 1, step 3: budesonide-formoterol one inhalation twice daily and as needed with a spacer, a written action plan, a smoke-free room, review in four to six weeks and spirometry in three monthscompletedGL-GINA-2025, GL-NAEPP-2020, GL-CMID-2026S

Goals

GoalTargetStatusOutcomeProvenance
Diabetes confirmed and classified within a week1898-02-16completedType 2 diabetes confirmed by A1c 9.4 percent and fasting glucose 172 mg/dL; GAD65 antibodies negative and C-peptide preservedS
A1c below 7 percent without hypoglycemia, in a way that fits his diet and fasts1898-10-27completedA1c 6.9 percent on metformin; no hypoglycemia; fasts kept safelyS
Blood pressure below 130/801898-03-23completedHome 128/80 and clinic 128/80 two weeks after starting losartanS
Albuminuria reduced and kidney function preserved1899-01-26activeUrine albumin-to-creatinine ratio down from 46 to 34 mg/g; eGFR 103; empagliflozin startedS
Falling asleep within 30 minutes on most nights1898-12-08activeAbout 45 minutes after four of six sessionsS

Functional Status

Mental Status